The estimated Net Worth of David M. Epstein is at least 9.13 百万$ dollars as of 27 June 2023. David Epstein owns over 25,000 units of Black Diamond Therapeutics Inc stock worth over 4,115,823$ and over the last 5 years he sold BDTX stock worth over 1,671,220$. In addition, he makes 3,346,080$ as President、 Chief Executive Officer、 Director at Black Diamond Therapeutics Inc.
David has made over 6 trades of the Black Diamond Therapeutics Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 25,000 units of BDTX stock worth 167,500$ on 27 June 2023.
The largest trade he's ever made was selling 25,000 units of Black Diamond Therapeutics Inc stock on 27 June 2023 worth over 167,500$. On average, David trades about 6,864 units every 91 days since 2020. As of 27 June 2023 he still owns at least 671,423 units of Black Diamond Therapeutics Inc stock.
You can see the complete history of David Epstein stock trades at the bottom of the page.
Dr. David M. Epstein Ph.D. serves as President, Chief Executive Officer, Director of the Company. Since January 2019, Dr. Epstein has served as an Adjunct Associate Professor for the Cancer and Stem Cell Biology Program at Duke-NUS Medical School. From April 2013 to December 2018, Dr. Epstein held positions at Duke-NUS Medical School, Singapore, where he founded and built Duke-NUS’s Center for Technology & Development. Dr. Epstein’s positions include Vice Dean, Innovation & Entrepreneurship, and Associate Professor in Cancer and Stem Biology. From June 2010 to March 2013, Dr. Epstein was Senior Vice President, Chief Scientific Officer and Site-Head for OSI Pharmaceuticals, Inc., a pharmaceutical company acquired by Astellas Pharma, Inc. From 2006 to 2010, Dr. Epstein served as Senior Vice President and Chief Scientific Officer, Oncology, at OSI Pharmaceuticals, Inc. until it was acquired by Astellas. Before joining OSI, from 2001 to 2006, Dr. Epstein served as Vice President, Biology, and from 2000 to 2003, as co-founder and a member of the board of directors at Archemix Corporation, a biotechnology company. From April 2013 to April 2015, Dr. Epstein served as a member of the board of directors at MetaStat, Inc., a precision medicine biotechnology company. Dr. Epstein earned a B.S. in Chemistry from Lewis & Clark College and a Ph.D. in Biochemistry at Brandeis University. Dr. Epstein completed a joint post-doctoral fellowship, leading a collaboration in protein structure, function and NMR dynamics between the labs of Steven Benkovic (Penn State) and Peter Wright at The Scripps Research Institute in La Jolla, California. Epstein is qualified to serve on our board of directors because of his considerable qualifications, attributes and skills, including his distinguished scientific background and experience in leadership roles in the biopharmaceutical industry.
As the President、 Chief Executive Officer、 Director of Black Diamond Therapeutics Inc, the total compensation of David Epstein at Black Diamond Therapeutics Inc is 3,346,080$. There are no executives at Black Diamond Therapeutics Inc getting paid more.
David Epstein is 61, he's been the President、 Chief Executive Officer、 Director of Black Diamond Therapeutics Inc since 2016. There are 4 older and 15 younger executives at Black Diamond Therapeutics Inc. The oldest executive at Black Diamond Therapeutics Inc is Robert Ingram, 77, who is the Independent Chairman of the Board.
David's mailing address filed with the SEC is C/O BLACK DIAMOND THERAPEUTICS, INC., ONE MAIN STREET, 14TH FLOOR, CAMBRIDGE, MA, 02142.
Over the last 5 years, insiders at Black Diamond Therapeutics Inc have traded over 26,407,257$ worth of Black Diamond Therapeutics Inc stock and bought 10,796,678 units worth 105,501,601$ . The most active insiders traders include Ali Behbahani、Rajeev M. Shah、Capital Management, L.P.Ra .... On average, Black Diamond Therapeutics Inc executives and independent directors trade stock every 21 days with the average trade being worth of 899,443$. The most recent stock trade was executed by Venture Capital Vi, L.P.Ver... on 28 August 2024, trading 221,600 units of BDTX stock currently worth 1,400,512$.
black diamond therapeutics, inc., a precision oncology medicine company, discovers and develops small molecule, tumor-agnostic therapies. its lead product candidate is bdtx-189, an inhibitor of non-canonical and oncogenic mutations of erbb kinases epidermal growth factor receptor (egfr) and tyrosine-protein kinase. the company is also developing allosteric-egfr mutation inhibitors; and various early stage pipeline programs targeting allosteric mutations in kinases related to cancer and/or rare genetic diseases. the company was formerly known as aset therapeutics, inc. and changed its name to black diamond therapeutics, inc. in january 2018. black diamond therapeutics, inc. was founded in 2014 and is headquartered in cambridge, massachusetts.
Black Diamond Therapeutics Inc executives and other stock owners filed with the SEC include: